<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373124</url>
  </required_header>
  <id_info>
    <org_study_id>7051</org_study_id>
    <nct_id>NCT02373124</nct_id>
  </id_info>
  <brief_title>Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial</brief_title>
  <official_title>Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the feasibility of a treatment paradigm that involves naturalistic
      cocaine use opportunities in the context of psychotherapy aimed at utilizing these
      opportunities therapeutically.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use</measure>
    <time_frame>5 weeks</time_frame>
    <description>Participants were provided choices to use up to 5 hits of cocaine on up to 2 occasions (cocaine versus money). Participants who chose cocaine (1 or more hits) during the first choice opportunity are administered a 52 minute infusion of 0.71 mg/kg ketamine the following day. Another choice opportunity occurs 24 hours later. The primary outcome is the choice participants made during these occasions</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cocaine Use Disorders</condition>
  <arm_group>
    <arm_group_label>open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52 minute infusion of NMDA antagonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion of NMDA antagonist</intervention_name>
    <description>52 minute infusion</description>
    <arm_group_label>open-label</arm_group_label>
    <other_name>NMDA antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion Method of Ascertainment

          1. Active cocaine dependence with at least 8 days of use or at least 4 binges of large
             amounts (&gt;$200/occasion) over the past 30 days, and displaying at least one positive
             utox during screening SCID, Psychiatric Interview, self-report, utox

          2. Physically healthy Laboratory tests (urinalysis, blood chemistry, 12-lead ECG in
             normal limits), physical examination, self-reported medical history

          3. No adverse reactions to study medications Subjects will be asked about previous
             exposure to ketamine and midazolam

          4. 21-55 years of age Self-reported age, verification with legal identification

          5. Capacity to consent and comply with study procedures, including sufficient proficiency
             in English A short written test about study procedures, SCID, psychiatric interview

          6. Seeking treatment Psychiatric Interview, self-report

        Exclusion Criterion Method of Ascertainment

          1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance induced psychosis, and current
             substance-induced mood disorder with HAMD score &gt; 12. Psychiatric Interview, SCID,
             HAMD

          2. Physiological dependence on another substance, such as alcohol, opioids, or
             benzodiazepines, excluding caffeine, nicotine, and cannabis SCID, Psychiatric
             Interview

          3. Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders SCID,
             Psychiatric Interview

          4. Current suicide risk or a history of suicide attempt within the past year SCID,
             Psychiatric Interview

          5. Pregnant or interested in becoming pregnant during the study period Blood and urine
             pregnancy testing, self-report

          6. Any of the following cardiac conditions: clinically significant left ventricular
             hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
             Laboratory tests (12-lead ECG in normal limits), physical examination, self-reported
             medical history

          7. Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), WBC &lt; 3.5, active hepatitis or other liver disease with
             elevated transaminase levels (&lt; 2-3 X upper limit of normal will be considered
             acceptable if PT/PTT is normal), renal failure (creat &gt; 2, BUN &gt;40), or untreated
             diabetes Physiological tests (urinalysis, blood chemistry, 12-lead ECG), physical
             examination, self-reported medical history

          8. Previous history of ketamine or midazolam misuse or abuse, and a history of an adverse
             reaction/experience with prior exposure to cocaine, ketamine or midazolam Physical
             examination, self-reported medical history

          9. Recent history of significant violence (past 2 years) SCID, Psychiatric Interview

         10. Abnormal pseudocholinesterase level Blood testing

         11. First degree relative with a psychotic disorder (bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychosis NOS) SCID, Psychiatric Interview

         12. BMI &gt; 35, or a history of documented obstructive sleep apnea Physical examination,
             self-reported medical history

         13. On psychotropic or other medications whose effect could be disrupted by participation
             in the study Psychiatric interview, self-reported medical history

         14. Patients who cannot comply with study procedures during the initial hospitalization
             phase Study Performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>elias dakwar</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2019</results_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Elias Dakwar</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open-label</title>
          <description>52 minute infusion of NMDA antagonist
infusion of NMDA antagonist: 52 minute infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open-label</title>
          <description>52 minute infusion of NMDA antagonist
infusion of NMDA antagonist: 52 minute infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="48" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use</title>
        <description>Participants were provided choices to use up to 5 hits of cocaine on up to 2 occasions (cocaine versus money). Participants who chose cocaine (1 or more hits) during the first choice opportunity are administered a 52 minute infusion of 0.71 mg/kg ketamine the following day. Another choice opportunity occurs 24 hours later. The primary outcome is the choice participants made during these occasions</description>
        <time_frame>5 weeks</time_frame>
        <population>medically healthy, treatment-seeking cocaine dependent individuals without a history of abuse of or adverse reaction to ketamine or benzodiazepines.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label</title>
            <description>52 minute infusion of NMDA antagonist
infusion of NMDA antagonist: 52 minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use</title>
          <description>Participants were provided choices to use up to 5 hits of cocaine on up to 2 occasions (cocaine versus money). Participants who chose cocaine (1 or more hits) during the first choice opportunity are administered a 52 minute infusion of 0.71 mg/kg ketamine the following day. Another choice opportunity occurs 24 hours later. The primary outcome is the choice participants made during these occasions</description>
          <population>medically healthy, treatment-seeking cocaine dependent individuals without a history of abuse of or adverse reaction to ketamine or benzodiazepines.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>first choice opportunity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>able to abstain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>continue to use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>second choice opportunity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>able to abstain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>continue to use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open-label</title>
          <description>52 minute infusion of NMDA antagonist
infusion of NMDA antagonist: 52 minute infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Dakwar, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467748728</phone>
      <email>elias.dakwar@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

